Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease

Ladan Zand, Vicente Torres, Timothy S. Larson, Bernard Francis King, Sanjeev M Sethi, Eric J. Bergstralh, Andrea Angioi, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. Methods Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. Results At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. Conclusions Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.

Original languageEnglish (US)
Pages (from-to)1290-1295
Number of pages6
JournalNephrology Dialysis Transplantation
Volume31
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Autosomal Dominant Polycystic Kidney
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin
Renal Circulation
Hemodynamics
Kidney
Healthy Volunteers
Kidney Diseases
Iothalamic Acid
Creatinine
Magnetic Resonance Spectroscopy
Therapeutics
Lipids
Serum
hippuric acid
Proteins

Keywords

  • ADPKD
  • HMG-CoA reductase inhibitor
  • Renal blood flow
  • Statins

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology
  • Transplantation

Cite this

@article{bcdf59e39bbb44ff80830865a333b0ba,
title = "Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease",
abstract = "Background To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. Methods Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. Results At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. Conclusions Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.",
keywords = "ADPKD, HMG-CoA reductase inhibitor, Renal blood flow, Statins",
author = "Ladan Zand and Vicente Torres and Larson, {Timothy S.} and King, {Bernard Francis} and Sethi, {Sanjeev M} and Bergstralh, {Eric J.} and Andrea Angioi and Fervenza, {Fernando Custodio}",
year = "2016",
month = "8",
day = "1",
doi = "10.1093/ndt/gfv394",
language = "English (US)",
volume = "31",
pages = "1290--1295",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease

AU - Zand, Ladan

AU - Torres, Vicente

AU - Larson, Timothy S.

AU - King, Bernard Francis

AU - Sethi, Sanjeev M

AU - Bergstralh, Eric J.

AU - Angioi, Andrea

AU - Fervenza, Fernando Custodio

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. Methods Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. Results At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. Conclusions Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.

AB - Background To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. Methods Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. Results At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. Conclusions Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.

KW - ADPKD

KW - HMG-CoA reductase inhibitor

KW - Renal blood flow

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84982181856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982181856&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfv394

DO - 10.1093/ndt/gfv394

M3 - Article

C2 - 26614268

AN - SCOPUS:84982181856

VL - 31

SP - 1290

EP - 1295

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 8

ER -